Corvus Pharmaceuticals Inc. Common Stock (CRVS)

About CRVS

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinic…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

37

Website

www.corvuspharma.com/

Fundamentals

1-day range

$13.98$14.6

Market cap

$1.17B

P/E (trailing)

—

P/E (forward)

-13.26

EPS (trailing)

$-0.62

Dividend yield

—

Beta

1.49

Avg. volume

1.10M

Forecasts

7 analyst ratings

Corvus Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CRVS

  Corvus Pharmaceuticals Inc. Common Stock

  $14.15

  ▼ 3.87%
  Market cap $1.17BP/E —
  $5.28$26.95
• SVRA

  Savara Inc. Common Stock

  $5.27

  ▼ 4.10%
  Market cap $1.19BP/E —
  $3.19$7.01
• ARDX

  Ardelyx Inc. Common Stock

  $3.81

  ▼ 0.26%
  Market cap $1.20BP/E —
  $3.73$8.4
• IVA

  Inventiva S.A. American Depository Shares

  $4.71

  ▼ 3.98%
  Market cap $1.10BP/E —
  $2.88$6.2
• SPTX

  Seaport Therapeutics Inc. Common Stock

  $24.04

  ▼ 8.42%
  Market cap $1.24BP/E —
• MNKD

  MannKind Corporation Common Stock

  $3.96

  ▼ 2.59%
  Market cap $1.24BP/E —
  $2.23$6.51
• ETON

  Eton Pharmaceuticals Inc. Common Stock

  $59.79

  ▼ 4.60%
  Market cap $1.26BP/E 150.92
  $14.27$66.37

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment
  SeekingAlpha · 8/27/2026
• Corvus Pharmaceuticals Says Phase 1/1b Soquelitinib T Cell Lymphoma Data Published In Blood Showed Objective Responses In 9 Of 24 Patients, Median Overall Survival Of 28.1 Months
  benzinga · 8/27/2026
• Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value
  SeekingAlpha · 8/12/2026
• Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement
  SeekingAlpha · 8/10/2026
• Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/7/2026
• Corvus Pharmaceuticals (NASDAQ:CRVS) Misses Q2 Loss Estimates as Clinical-Stage Spending Continues
  ChartMill · 8/6/2026
• Corvus Pharma Q2 EPS $(0.19) Misses $(0.17) Estimate
  Benzinga · 8/6/2026

• David Scott Moore · June 11, 2026 · Grant

  15.0K
• David Scott Moore · June 11, 2026 · Buy

  21.7K @ $11.53
• van den Broek Richard · June 11, 2026 · Grant

  15.0K
• Linda Grais · June 11, 2026 · Grant

  15.0K
• Peter A. Thompson · June 11, 2026 · Grant

  15.0K
• Ian T. Clark · June 11, 2026 · Grant

  15.0K
• Richard A. Miller, MD · May 18, 2026 · Buy

  1.9K @ $12.01
• Richard A. Miller, MD · May 18, 2026 · Buy

  5.0K @ $12.05
• Chan Andrew C. · April 23, 2026 · Grant

  30.0K

Institutional Ownership

March 31, 2026

Total shares held

70.33M

Total value held

$983.35M

Institutional holders

161